Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoIpower: Neoadjuvant Icotinib + Chemotherapy in EGFR+ NSCLC
NCT05104788Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib in lung adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major Pathological Response at 12 weeks. Started Oct 2021; status: recruiting.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05104788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104788.